Research Article
The Prognostic Role and Relationship between E2F1 and SV40 in Diffuse Large B-Cell Lymphoma of Egyptian Patients
Table 3
Relationship of E2F1 expression with the clinicopathological data and expression of SV40 in DLBCL cases.
| | Variables | E2F1 among DLBCL |
Test of significance and value | ≤10
() | >10
() | | No (%) | No (%) |
| | Age | | | | | ( ± SD) | 58.5 ± 6.8 | 50.4 ± 14.5 | = 2.36
| | Median | 69.0 | 56 | | Range | 32–75 | 41–70 | | Age | | | | | <60 | 16 (33) | 33 (67) | = 11.25
| | ≥60 | 25 (69) | 11 (31) | | Gender | | | | | Male | 21 (50) | 21 (50) | = 0.10
0.748 | | Female | 20 (47) | 23 (53) | | Primary site of involvement | | | | | Nodal | 29 (52) | 27 (48) | = 0.83
0.363 | | Extranodal | 12 (41) | 17 (59) | | Number of involved extranodal sites | | | | | 0 | 25 (3) | 22 (47) |
FE = 1.21
0.553 | | 1-2 | 13 (41) | 19 (59) | | >2 | 3 (50) | 3 (50) | | Status (nodal = 56) | | | | | Generalized | 9 (40) | 9 (60) |
FE = 0.809
0.779 | | Localized | 17 (53) | 21 (47) | | Size (cm) | | | | | ≤10 | 36 (49) | 6 (51) | = 0.04
0.843 | | >10 | 5 (45) | 38 (55) | | Stage grouping | | | | | Early | 25 (52) | 23 (48) |
= 0.65
0.419 | | Advanced | 16 (43) | 21 (57) | | PS | | | | | <2 | 7 (50) | 7 (50) |
FE = 1.088
1.000 | | ≥2 | 34 (48) | 37 (52) | | B symptoms | | | | | Present | 23 (45) | 28 (55) | = 0.50
0.478 | | Absent | 18 (53) | 16 (47) | | LDH | | | | | Normal | 3 (27) | 8 (73) | = 2.22
0.136 | | Elevated | 38 (51) | 36 (49) | | Prognostic group of R-IPI | | | | | Good | 14 (48) | 15 (52) | = 0.00
0.996 | | Poor | 27 (48) | 29 (52) | | Risk groups of AAIPI ≥60 | | | | | Low | 12 (86) | 2 (14) |
FE = 3.09
0.233 | | Intermediate | 5 (63) | 3 (37) | | High | 6 (55) | 5 (45) | | Risk groups of AAIPI <60 | | | | | Low | 2 (15) | 11 (85) | FE = 5.85
| | Intermediate | 10 (66) | 8 (44) | | High | 6 (29) | 15 (71) | | Type of DLBCL | | | | | Germinal | 22 (45) | 27 (55) |
FE = 1.34
0.80 | | Nongerminal | 18 (50) | 18 (50) | | Necrosis | | | | | Present | 5 (36) | 9 (64) | = 1.05
0.305 | | Absent | 36 (51) | 35 (49) | | Necrosis (%) | | | | | ± SD | 44.0 ± 23.0 | 28.9 ± 21.5 | = 1.15
0.249 | | Median | 60 | 20 | | Range | 10–60 | 10–80 | | Mitosis | | | | | ± SD | 14.5 ± 4.4 | 29.9 ± 6.3 | = 12.98
| | Median | 13 | 34 | | Range | 12–14 | 24–43 | | Ki-67 LI | | | | | <50 | 41 (82) | 9 (18) | = 55.44
| | ≥50 | 0 (0) | 35 (100) | | Apoptosis | | | | | ± SD | 10.5 ± 4.9 | 16.3 ± 6.4 | = 4.29
| | Median | 11 | 17 | | Range | 4–26 | 5–25 | | SV40 | | | | | Positive | 1 (33) | 2 (67) |
FE = 0.28
1.00 | | Negative | 40 (49) | 42 (51) |
|
|
R-IPI: revised international prognostic index; AAIPI: age adjusted international prognostic index; PS: performance status; LDH: lactate dehydrogenase; significant; highly significant; -test: Student’s -test; : Mann-Whitney test; FE: Fisher’s exact test; : Chi-square test; Ki-67 LI: Ki-67 labeling index; DLBCL: diffuse large B-cell lymphoma.
|
